J&J's TECVAYLI/DARZALEX Combo Secures FDA Approval, Poised to Reshape Multiple Myeloma Treatment
Event summary
- Johnson & Johnson received FDA approval for TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® for relapsed/refractory multiple myeloma (RRMM) on March 5, 2026.
- The approval is based on Phase 3 MajesTEC-3 data demonstrating statistically significant improvements in progression-free survival (PFS) and overall survival (OS) compared to standard of care.
- The MajesTEC-3 trial showed an 83% three-year PFS rate versus 30% in the control arm, and an OS rate of 83.3% versus 65.0%.
- The FDA selected the teclistamab MajesTEC-3 sBLA for the Commissioner's National Priority Voucher Pilot Program, indicating a strategic priority.
The big picture
The approval of TECVAYLI plus DARZALEX FASPRO represents a significant advancement in RRMM treatment, offering a potentially new standard of care and addressing a critical unmet need for patients experiencing relapse. This approval underscores the growing importance of bispecific antibodies in oncology and highlights J&J’s continued dominance in the hematology space. The FDA’s prioritization of the sBLA suggests a broader strategic interest in accelerating innovative therapies for serious diseases.
What we're watching
- Market Adoption
- The speed of adoption by oncologists will depend on reimbursement rates and the demonstrated ability to manage potential adverse events, particularly cytokine release syndrome and ICANS.
- Competitive Landscape
- The emergence of other bispecific antibody therapies and novel treatment approaches will likely intensify competition and pressure pricing in the RRMM space.
- Clinical Expansion
- How quickly J&J expands the approved indication to earlier lines of therapy, potentially as early as first-line treatment, will be a key indicator of the therapy’s long-term impact.
Related topics